158 related articles for article (PubMed ID: 3113703)
1. Effects of nandrolone decanoate on forearm mineral density and calcium metabolism in osteoporotic postmenopausal women.
Need AG; Morris HA; Hartley TF; Horowitz M; Nordin BE
Calcif Tissue Int; 1987 Jul; 41(1):7-10. PubMed ID: 3113703
[TBL] [Abstract][Full Text] [Related]
2. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
Gennari C; Agnusdei D; Gonnelli S
Minerva Endocrinol; 1989; 14(1):69-74. PubMed ID: 2659955
[TBL] [Abstract][Full Text] [Related]
3. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
Need AG; Horowitz M; Walker CJ; Chatterton BE; Chapman IC; Nordin BE
Bone; 1989; 10(1):3-6. PubMed ID: 2736154
[TBL] [Abstract][Full Text] [Related]
4. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
Gennari C; AgnusDei D; Gonnelli S; Nardi P
Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
[TBL] [Abstract][Full Text] [Related]
5. [Effects of nandrolone decanoate on bone mineral content and intestinal absorption of calcium].
Nuti R; Righi GA; Turchetti V; Vattimo A
Minerva Med; 1984 Jan; 75(3-4):109-13. PubMed ID: 6366617
[TBL] [Abstract][Full Text] [Related]
6. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
Need AG; Horowitz M; Morris HA; Walker CJ; Nordin BE
Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral content, cortical thickness and fracture rate in osteoporotic women after withdrawal of treatment with nandrolone decanoate, 1-alpha hydroxyvitamin D3, or intermittent calcium infusions.
Geusens P; Dequeker J; Verstraeten A; Nijs J; Van Holsbeeck M
Maturitas; 1986 Dec; 8(4):281-9. PubMed ID: 3574141
[TBL] [Abstract][Full Text] [Related]
8. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Johansen JS; Hassager C; Pødenphant J; Riis BJ; Hartwell D; Thomsen K; Christiansen C
Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
[TBL] [Abstract][Full Text] [Related]
9. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women.
Need AG; Horowitz M; Bridges A; Morris HA; Nordin BE
Arch Intern Med; 1989 Jan; 149(1):57-60. PubMed ID: 2912415
[TBL] [Abstract][Full Text] [Related]
10. Long-term effect of nandrolone decanoate, 1 alpha-hydroxyvitamin D3 or intermittent calcium infusion therapy on bone mineral content, bone remodeling and fracture rate in symptomatic osteoporosis: a double-blind controlled study.
Geusens P; Dequeker J
Bone Miner; 1986 Sep; 1(4):347-57. PubMed ID: 3333018
[TBL] [Abstract][Full Text] [Related]
11. Effects of nandrolone decanoate on bone mass in established osteoporosis.
Passeri M; Pedrazzoni M; Pioli G; Butturini L; Ruys AH; Cortenraad MG
Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
[TBL] [Abstract][Full Text] [Related]
12. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women.
Hassager C; Pødenphant J; Riis BJ; Johansen JS; Jensen J; Christiansen C
Metabolism; 1989 Mar; 38(3):238-42. PubMed ID: 2645503
[TBL] [Abstract][Full Text] [Related]
13. Effect of calcium supplementation on urinary hydroxyproline in osteoporotic postmenopausal women.
Horowitz M; Need AG; Philcox JC; Nordin BE
Am J Clin Nutr; 1984 Jun; 39(6):857-9. PubMed ID: 6720619
[TBL] [Abstract][Full Text] [Related]
14. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis.
Horowitz M; Wishart JM; Need AG; Morris HA; Nordin BE
Clin Endocrinol (Oxf); 1993 Dec; 39(6):649-55. PubMed ID: 8287582
[TBL] [Abstract][Full Text] [Related]
15. Nandrolone decanoate: pharmacological properties and therapeutic use in osteoporosis.
Geusens P
Clin Rheumatol; 1995 Sep; 14 Suppl 3():32-9. PubMed ID: 8846659
[TBL] [Abstract][Full Text] [Related]
16. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate.
Adami S; Fossaluzza V; Rossini M; Bertoldo F; Gatti D; Zamberlan N; Lo Cascio V
Bone Miner; 1991 Oct; 15(1):73-81. PubMed ID: 1747568
[TBL] [Abstract][Full Text] [Related]
17. Comparison of calcium, calcitriol, ovarian hormones and nandrolone in the treatment of osteoporosis.
Need AG; Chatterton BE; Walker CJ; Steurer TA; Horowitz M; Nordin BE
Maturitas; 1986 Dec; 8(4):275-80. PubMed ID: 3574140
[TBL] [Abstract][Full Text] [Related]
18. Treatment of postmenopausal hyperparathyroidism with norethindrone. Effects on biochemistry and forearm mineral density.
Horowitz M; Wishart J; Need AG; Morris H; Philcox J; Nordin BE
Arch Intern Med; 1987 Apr; 147(4):681-5. PubMed ID: 3827457
[TBL] [Abstract][Full Text] [Related]
19. The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women.
Nordin BE; Robertson A; Seamark RF; Bridges A; Philcox JC; Need AG; Horowitz M; Morris HA; Deam S
J Clin Endocrinol Metab; 1985 Apr; 60(4):651-7. PubMed ID: 3156144
[TBL] [Abstract][Full Text] [Related]
20. A controlled trial of nandrolone decanoate in the treatment of rheumatoid arthritis in postmenopausal women.
Bird HA; Burkinshaw L; Pearson D; Atkinson PJ; Leatham PA; Hill J; Raven A; Wright V
Ann Rheum Dis; 1987 Mar; 46(3):237-43. PubMed ID: 3555359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
